ArticleBMC cancer2023
First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 29 citations in OpenAlex.
- Trial
- Consolidative thoracic radiotherapy after first-line chemoimmunotherapy in extensive-stage small-cell lung cancer: a multicenter retrospective study.Translational lung cancer research · 2026Article
- ATM functions as a rheostat of metabolic stress in small-cell lung cancer.bioRxiv : the preprint server for biology · 2026Article
- Role of thoracic radiotherapy for extensive-stage small cell lung cancer in the era of immunotherapy: a review of current evidence.Frontiers in immunology · 2026Review
- Closing the evidence gap in older adults with extensive-stage small-cell lung cancer: a CGA-guided, risk-adapted treatment framework.Therapeutic advances in medical oncology · 2026Review
- Real-world treatment patterns and outcomes of chemo-immunotherapy with or without radiotherapy in extensive-stage small cell lung cancer: the durvalumab expanded access cohort.Frontiers in oncology · 2026Article
- Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis.Frontiers in immunology · 2026Article
- Chemoradioimmunotherapy versus chemoimmunotherapy or chemoradiotherapy in extensive-stage small-cell lung cancer: A retrospective analysis of survival outcomes.Precision radiation oncology · 2025Article
- Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study.Thoracic cancer · 2025Observational
- Graded prognostic assessment model for bone-only metastasis in extensive-stage small cell lung cancer.BMC pulmonary medicine · 2025Article
- Meta-analysis of the efficacy and safety of thoracic radiotherapy for extensive-stage small cell lung cancer in the era of immunotherapy.Oncology letters · 2025Article
- Early radiotherapy improved survival of patients with extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy.BMC cancer · 2025Article
- Evaluating the role of consolidative chest radiotherapy after chemo-immunotherapy in extensive-stage small cell lung cancer: a retrospective study.Discover oncology · 2025Article
- Benefit of Consolidation Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer Patients Treated with Immunotherapy: Data from Slovenian Cohort.International journal of molecular sciences · 2025Article
- Current and future therapies for small cell lung carcinoma.Journal of hematology & oncology · 2025Review
- Advancements in consolidative thoracic radiotherapy following first-line immunotherapy in conjunction with chemotherapy for extensive-stage small cell lung cancer.Frontiers in immunology · 2025Review
- Efficacy and safety of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in patients with extensive-stage small-cell lung cancer: a retrospective cohort study.Translational lung cancer research · 2024Article
- Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report.Translational lung cancer research · 2024Article
- The role of radiotherapy in extensive-stage small cell lung cancer: insights from treatment failure patterns in the era of immunotherapy.BMC cancer · 2024Article
- Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundImmunotherapy has made significant advances in the treatment of extensive-stage small-cell lung cancer (ES-SCLC), but data in combination with radiotherapy are scarce. This study aims to assess the safety and efficacy of chemoimmunotherapy combined with thoracic radiotherapy in patients with ES-SCLC.
methodsThis single-center retrospective study analyzed patients with ES-SCLC who received standard platinum-etoposide chemotherapy combined with atezolizumab or durvalumab immunotherapy as induction treatment, followed by consolidative thoracic radiotherapy (CTRT) before disease progression in the first-line setting. Adverse events during radiotherapy with or without maintenance immunotherapy and survival outcomes were assessed.
resultsBetween December 2019 and November 2021, 36 patients with ES-SCLC were identified to have received such treatment modality at one hospital. The number of metastatic sites at diagnosis was 1-4. The biological effective dose of CTRT ranged from 52 to 113 Gy. Only two patients (6%) developed grade 3 toxic effect of thrombocytopenia, but none experienced grade 4 or 5 toxicity. Four patients developed immune-related pneumonitis during the induction treatment period but successfully completed later CTRT. The rate of radiation-related pneumonitis was 8% with grades 1-2 and well tolerated. The median progression-free survival (PFS) was 12.8 months, but the median overall survival (OS) was not determined. The estimated 1-year OS was 80.2% and 1-year PFS was 53.4%.
conclusionsImmunotherapy combined with CTRT for ES-SCLC is safe and has ample survival benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.